Eiger BioPharmaceuticals Inc
NASDAQ:EIGR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Eiger BioPharmaceuticals Inc
Eiger BioPharmaceuticals Inc
Other Long-Term Assets
Eiger BioPharmaceuticals Inc
Other Long-Term Assets Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Other Long-Term Assets Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Eiger BioPharmaceuticals Inc
NASDAQ:EIGR
|
Other Long-Term Assets
$360k
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-17%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Long-Term Assets
$9.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
51%
|
CAGR 10-Years
27%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Long-Term Assets
$4.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Long-Term Assets
$9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
39%
|
CAGR 10-Years
19%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Long-Term Assets
$2.8B
|
CAGR 3-Years
49%
|
CAGR 5-Years
13%
|
CAGR 10-Years
75%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Long-Term Assets
$3.2B
|
CAGR 3-Years
55%
|
CAGR 5-Years
27%
|
CAGR 10-Years
29%
|
See Also
What is Eiger BioPharmaceuticals Inc's Other Long-Term Assets?
Other Long-Term Assets
360k
USD
Based on the financial report for Dec 31, 2023, Eiger BioPharmaceuticals Inc's Other Long-Term Assets amounts to 360k USD.
What is Eiger BioPharmaceuticals Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-17%
Over the last year, the Other Long-Term Assets growth was -72%. The average annual Other Long-Term Assets growth rates for Eiger BioPharmaceuticals Inc have been -55% over the past three years , -2% over the past five years , and -17% over the past ten years .
You don't have any saved screeners yet
